Organon & Co
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
21% more first-time investments, than exits
New positions opened: 123 | Existing positions closed: 102
18% more call options, than puts
Call options by funds: $25.5M | Put options by funds: $21.7M
2.79% more ownership
Funds ownership: 77.02% [Q3] → 79.81% (+2.79%) [Q4]
1% more funds holding
Funds holding: 711 [Q3] → 716 (+5) [Q4]
13% less repeat investments, than reductions
Existing positions increased: 206 | Existing positions reduced: 237
17% less funds holding in top 10
Funds holding in top 10: 6 [Q3] → 5 (-1) [Q4]
19% less capital invested
Capital invested by funds: $3.79B [Q3] → $3.07B (-$720M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$16
13%
upside
Avg. target
$20
42%
upside
High target
$24
70%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
Barclays Balaji Prasad 30% 1-year accuracy 13 / 44 met price target | 70%upside $24 | Overweight Maintained | 14 Feb 2025 |
Morgan Stanley Terence Flynn 37% 1-year accuracy 7 / 19 met price target | 13%upside $16 | Equal-Weight Maintained | 14 Feb 2025 |
Financial journalist opinion
Based on 9 articles about OGN published over the past 30 days
Positive
Zacks Investment Research
6 hours ago
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Neutral
Business Wire
8 hours ago
Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announced it has acquired regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion.
Neutral
Business Wire
4 days ago
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11
SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)--Henlius and Organon announced the European Medicines Agency validates filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11.
Neutral
Zacks Investment Research
4 days ago
Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know
Organon (OGN) closed the most recent trading day at $14.56, moving -1.02% from the previous trading session.
Neutral
Zacks Investment Research
1 week ago
Organon (OGN) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Organon (OGN) stood at $15.39, denoting a -1.35% change from the preceding trading day.
Positive
Zacks Investment Research
1 week ago
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Neutral
Zacks Investment Research
1 week ago
Organon (OGN) Advances While Market Declines: Some Information for Investors
Organon (OGN) concluded the recent trading session at $15.70, signifying a +0.51% move from its prior day's close.
Positive
Seeking Alpha
2 weeks ago
Why Organon Is A Top Pick For Income Investors
In mid-February, Organon pleasantly surprised me with its financial results for the fourth quarter of 2024. So, sales of Hadlima, a biosimilar to Humira, amounted to $44 million in the last three months of 2024, an increase of 83.3% year-on-year. Organon's dividend yield is 7.32%, which is significantly higher than that of the healthcare sector.
Neutral
Business Wire
3 weeks ago
New Analysis of Organon's VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a focus on women's health, today announced results from an analysis of the Phase 3 ADORING 3 open-label, long-term extension study evaluating VTAMA® (tapinarof) cream, 1% once daily in adults and children 2 years of age and older with atopic dermatitis (AD), also known as eczema. The findings demonstrate that AD disease activity remained mild in patients who had achieved treatment success and subsequently.
Positive
Benzinga
1 month ago
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Charts implemented using Lightweight Charts™